Bullous systemic lupus erythematosus (BSLE) is a rare and severe form of cutaneous lupus erythematosus that presents with blistering lesions. It is a manifestation of systemic lupus erythematosus ...

or lichen planus-lupus erythematosus overlap. However, histologic, immunofluorescent, immunoelectron microscopic, and immunoblot studies revealed findings compatible with bullous SLE. Our patient ...

For patients with moderately to severely active systemic lupus erythematosus (SLE), anifrolumab is associated with less organ ...

S L E is a chronic multisystem autoimmune disease in which cardiovascular disease is a leading cause of mortality, with a ...

Background SLE is a systemic autoimmune disease with a large number of common risk gene variants, but several rare gene ...

In the United States, SLE treatment trends between 2007 and 2023 show a continued reliance on glucocorticoids, despite advances in steroid-sparing agents.

The U.S. Food and Drug Administration (FDA) has granted fast track status to ADI-001, Adicet Bio ’s CAR T-cell therapy for ...

Cabaletta’s new data slice for its investigational CD19-CAR T cell therapy shows “robust benefit” for patients with lupus and ...

Combination therapies with immunosuppressive and biological agents in systemic lupus erythematosus: evidence on efficacy and safety. Combination Efficacy Safety Study design Ref. MMF + tacrolimus ...

Lupus can do irreversible harm to a person's organs, damaging the lungs, kidneys, heart, liver and other vital organs through ...

Systemic lupus erythematosus (SLE), also known as lupus, is an autoimmune disease that happens when the body’s defence system, which is supposed to help our body fight infections, turns against ...

Adicet Bio, Inc. (ACET), a clinical stage biotechnology company, Wednesday said it received Fast Track Designation from the U.S. Food ...